Evidence map›Paper›PMID 38570511›Full record

ArticleNPJ Parkinson's disease2024

Influences of amyloid-β and tau on white matter neurite alterations in dementia with Lewy bodies.

Elijah Mak, Robert I Reid, Scott A Przybelski, Timothy G Lesnick, Christopher G Schwarz, Matthew L Senjem, Sheelakumari Raghavan, Prashanthi Vemuri, Clifford R Jack, Hoon Ki Min and 19 more

Open access · goldAbstract read
In one paragraph

Article in NPJ Parkinson's disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
4.0field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Observational
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors at 5 institutions in 2 countries.

Elijah MakDepartment of Radiology, Mayo Clinic, Rochester, MN, USA.
Robert I ReidDepartment of Radiology, Mayo Clinic, Rochester, MN, USA.
Scott A PrzybelskiDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.
Timothy G LesnickDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.
Christopher G SchwarzDepartment of Radiology, Mayo Clinic, Rochester, MN, USA.ORCID http://orcid.org/0000-0002-1466-8357
Matthew L SenjemDepartment of Radiology, Mayo Clinic, Rochester, MN, USA.ORCID http://orcid.org/0000-0001-9308-9275
Sheelakumari RaghavanDepartment of Radiology, Mayo Clinic, Rochester, MN, USA.
Prashanthi VemuriDepartment of Radiology, Mayo Clinic, Rochester, MN, USA.
Clifford R JackDepartment of Radiology, Mayo Clinic, Rochester, MN, USA.ORCID http://orcid.org/0000-0001-7916-622X
Hoon Ki MinDepartment of Radiology, Mayo Clinic, Rochester, MN, USA.
Manoj K JainDepartment of Radiology, Mayo Clinic, Jacksonville, FL, USA.
Toji MiyagawaDepartment of Neurology, Mayo Clinic, Rochester, MN, USA.
Leah K ForsbergDepartment of Neurology, Mayo Clinic, Rochester, MN, USA.
Julie A FieldsDepartment of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, USA.
Rodolfo SavicaDepartment of Neurology, Mayo Clinic, Rochester, MN, USA.
Jonathan Graff-RadfordDepartment of Neurology, Mayo Clinic, Rochester, MN, USA.
David T JonesDepartment of Neurology, Mayo Clinic, Rochester, MN, USA.
Hugo BothaDepartment of Neurology, Mayo Clinic, Rochester, MN, USA.
Erik K St LouisDepartment of Neurology, Mayo Clinic, Rochester, MN, USA.
David S KnopmanDepartment of Neurology, Mayo Clinic, Rochester, MN, USA.
Vijay K RamananDepartment of Neurology, Mayo Clinic, Rochester, MN, USA.
Dennis W DicksonDepartment of Psychiatry and Psychology, Mayo Clinic, Jacksonville, FL, USA.ORCID http://orcid.org/0000-0001-7189-7917
Neill R Graff-RadfordLaboratory of Medicine and Pathology, Mayo Clinic, Jacksonville, FL, USA.
Tanis J FermanDepartment of Neurology, Mayo Clinic, Jacksonville, FL, USA.
Ronald C PetersenDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.
Val J LoweDepartment of Radiology, Mayo Clinic, Rochester, MN, USA.
Bradley F BoeveDepartment of Neurology, Mayo Clinic, Rochester, MN, USA.ORCID http://orcid.org/0000-0002-4153-8187
John T O'BrienDepartment of Psychiatry, University of Cambridge, Cambridge, UK.
Kejal KantarciDepartment of Radiology, Mayo Clinic, Rochester, MN, USA. kejal.kantarci@mayo.edu.ORCID http://orcid.org/0000-0002-8001-2081
Mayo Clinic in Arizona · USWinnMed · USMayo Clinic · USMayo Clinic in Florida · USUniversity of Cambridge · GB

Funding

SUPPLEMENT TO ALZHEIMERS DISEASE PATIENT REGISTRYU01AG006786 · NIA · MAYO CLINIC ROCHESTER · PI GRAFF-RADFORD, JONATHAN, JACK, CLIFFORD R. · 1986 to 2023
$49.6M
THE PGRN/TDP-43 AXIS IN ALZHEIMER?S DISEASE AND NEURODEGENERATIONP50AG016574 · NIA · MAYO CLINIC ROCHESTER · PI PETERSEN, RONALD C · 1999 to 2018
$36.9M
Longitudinal Imaging Biomarkers of Prodromal DLBU01NS100620 · NINDS · MAYO CLINIC ROCHESTER · PI Bradley F Boeve, KEJAL KANTARCI · 2017 to 2026
$19.2M
Rochester Epidemiology ProjectR01AG034676 · NIA · MAYO CLINIC ROCHESTER · PI ROCCA, WALTER A, ST SAUVER, JENNIFER LYNN · 2010 to 2019
$9.5M
Investigating Resistance and Resilience Mechanisms in Alzheimer’s DiseaseR01AG056366 · NIA · MAYO CLINIC ROCHESTER · PI PRASHANTHI VEMURI · 2017 to 2026
$7.0M
Disease pathways in the population determined by amyloid, tau, and neurodegeneration imaging biomarkersR37AG011378 · NIA · MAYO CLINIC ROCHESTER · PI CLIFFORD R. JACK · 2018 to 2026
$6.8M
Validating the New Criteria for Preclinical Alzheimer's diseaseR01AG041851 · NIA · MAYO CLINIC ROCHESTER · PI JACK, CLIFFORD R., KNOPMAN, DAVID S · 2012 to 2021
$6.3M
Development, Validation, and Application of an Imaging based CVD ScaleR01NS097495 · NINDS · MAYO CLINIC ROCHESTER · PI VEMURI, PRASHANTHI · 2016 to 2020
$2.9M
Interdisciplinary Infrastructure for Aging Research: Rochester Epidemiology ProjectR33AG058738 · NIA · MAYO CLINIC ROCHESTER · PI LEBRASSEUR, NATHAN K, OLSON, JANET E · 2020 to 2022
$2.4M
EXTRAMURAL RES FACIL IMPROVEMENT PROG: POLYCYSTIC KIDNEY DISEASE, RENAL STUDIES,C06RR018898 · NCRR · MAYO CLINIC · PI BURNETT, JOHN C · 2004 to 2004
$2.3M
Pathological basis of MRS and DTI changes in neurodegenerative dementiaR01AG040042 · NIA · MAYO CLINIC ROCHESTER · PI KANTARCI, KEJAL · 2011 to 2015
$1.6M
NCRR NIH HHS C06 RR018898NIA NIH HHS P50 AG016574NIA NIH HHS R01 AG034676NIA NIH HHS R01 AG040042NIA NIH HHS R01 AG041851NIA NIH HHS R01 AG056366NIA NIH HHS R33 AG058738NIA NIH HHS R37 AG011378NIA NIH HHS U01 AG006786NINDS NIH HHS R01 NS097495NINDS NIH HHS U01 NS100620
6 · The paper itself

Abstract

Dementia with Lewy bodies (DLB) is a neurodegenerative condition often co-occurring with Alzheimer's disease (AD) pathology. Characterizing white matter tissue microstructure using Neurite Orientation Dispersion and Density Imaging (NODDI) may help elucidate the biological underpinnings of white matter injury in individuals with DLB. In this study, diffusion tensor imaging (DTI) and NODDI metrics were compared in 45 patients within the dementia with Lewy bodies spectrum (mild cognitive impairment with Lewy bodies (n = 13) and probable dementia with Lewy bodies (n = 32)) against 45 matched controls using conditional logistic models. We evaluated the associations of tau and amyloid-β with DTI and NODDI parameters and examined the correlations of AD-related white matter injury with Clinical Dementia Rating (CDR). Structural equation models (SEM) explored relationships among age, APOE ε4, amyloid-β, tau, and white matter injury. The DLB spectrum group exhibited widespread white matter abnormalities, including reduced fractional anisotropy, increased mean diffusivity, and decreased neurite density index. Tau was significantly associated with limbic and temporal white matter injury, which was, in turn, associated with worse CDR. SEM revealed that amyloid-β exerted indirect effects on white matter injury through tau. We observed widespread disruptions in white matter tracts in DLB that were not attributed to AD pathologies, likely due to α-synuclein-related injury. However, a fraction of the white matter injury could be attributed to AD pathology. Our findings underscore the impact of AD pathology on white matter integrity in DLB and highlight the utility of NODDI in elucidating the biological basis of white matter injury in DLB.

Identifiers

PMID38570511
PMCPMC10991290
OpenAlexW4393859366

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.